DE60118593D1 - Verfahren zur herstellung von kristallinem n-formimidoylthienamycin-monohydrat (imipenem-monohydrat) - Google Patents

Verfahren zur herstellung von kristallinem n-formimidoylthienamycin-monohydrat (imipenem-monohydrat)

Info

Publication number
DE60118593D1
DE60118593D1 DE60118593T DE60118593T DE60118593D1 DE 60118593 D1 DE60118593 D1 DE 60118593D1 DE 60118593 T DE60118593 T DE 60118593T DE 60118593 T DE60118593 T DE 60118593T DE 60118593 D1 DE60118593 D1 DE 60118593D1
Authority
DE
Germany
Prior art keywords
monohydrate
formimidoylthienamycin
imipenem
preparing crystalline
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60118593T
Other languages
German (de)
English (en)
Inventor
Yatendra Kumar
Neera Tewari
Ram Chander Aryan
Bishwa Prakash Rai
Seema Ahuja
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11097114&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60118593(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Application granted granted Critical
Publication of DE60118593D1 publication Critical patent/DE60118593D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D477/00Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/16Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
    • C07D477/20Sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DE60118593T 2000-11-03 2001-11-05 Verfahren zur herstellung von kristallinem n-formimidoylthienamycin-monohydrat (imipenem-monohydrat) Expired - Lifetime DE60118593D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN983DE2000 IN191798B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2000-11-03 2000-11-03
PCT/IB2001/002069 WO2002036594A1 (en) 2000-11-03 2001-11-05 Process for the preparation of crystalline n-formimidoyl thienamycin monohydrate (imipenem monohydrate)

Publications (1)

Publication Number Publication Date
DE60118593D1 true DE60118593D1 (de) 2006-05-18

Family

ID=11097114

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60118593T Expired - Lifetime DE60118593D1 (de) 2000-11-03 2001-11-05 Verfahren zur herstellung von kristallinem n-formimidoylthienamycin-monohydrat (imipenem-monohydrat)

Country Status (19)

Country Link
US (1) US7078534B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP1334105B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2004525084A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR20030059812A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN100445284C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE322495T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2002212591A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BG (1) BG107852A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2427762C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE60118593D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK1334105T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA006442B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EE (1) EE200300206A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2261494T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN191798B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA03003916A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT1334105E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2002036594A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200303338B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK15092003A3 (sk) 2001-05-18 2004-09-08 Ranbaxy Laboratories Limited Spôsob izolácie kryštalického imipenému
EP1395587B1 (en) * 2001-05-18 2009-07-29 Ranbaxy Laboratories Limited Process for the preparation of imipenem
CN1522235A (zh) * 2001-05-18 2004-08-18 ʵ 制备无定形西司他汀钠的方法
US20040198973A1 (en) * 2001-08-13 2004-10-07 Tsujii Masahiko Process for preparation of carbapenem antibiotics
JP2005509037A (ja) 2001-11-16 2005-04-07 ランバクシー ラボラトリーズ リミテッド 結晶イミペネム製造方法
US6537985B1 (en) * 2001-11-30 2003-03-25 Phoenix Scientific, Inc. Antibiotic formulation and a method of making this formulation
MXPA06001115A (es) * 2003-12-09 2006-04-11 Choongwae Pharm Co Un proceso nuevo para la preparacion de imipenem.
KR100848751B1 (ko) * 2006-11-10 2008-07-25 제일약품주식회사 이미페넴의 제조방법
KR100848752B1 (ko) * 2006-11-10 2008-07-25 제일약품주식회사 티에나마이신 용매화합물 및 그의 제조방법
EP2209787A4 (en) * 2007-10-08 2011-08-03 Orchid Chemicals & Pharm Ltd METHOD FOR PRODUCING A CARBAPENEM ANTIBIOTICS
CN108623598A (zh) * 2018-05-21 2018-10-09 重庆天地药业有限责任公司 一种亚胺培南中间体及亚胺培南的制备方法
CN111413427A (zh) * 2020-04-08 2020-07-14 苏州和合医学检验有限公司 超滤前处理高效液相色谱测定血浆中亚胺培南含量的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4194047A (en) 1975-11-21 1980-03-18 Merck & Co., Inc. Substituted N-methylene derivatives of thienamycin
US4260543A (en) * 1978-07-03 1981-04-07 Merck & Co., Inc. Crystalline N-formimidoyl thienamycin
JP3048196B2 (ja) 1991-06-20 2000-06-05 第一製薬株式会社 カルバペネム誘導体
ES2101119T3 (es) 1991-10-01 1997-07-01 Procter & Gamble Pharma Procedimiento para preparar quinolonil-lactamas antimicrobianas.
FI104822B (fi) 1992-09-09 2000-04-14 Sankyo Co Menetelmä karbapeneemi- ja peneemiyhdisteiden valmistamiseksi
US5245069A (en) * 1992-10-27 1993-09-14 Merck & Co., Inc. Process for the preparation of bis(aryl)-phosphorohalidates
US5872250A (en) * 1997-07-30 1999-02-16 Merck & Co., Inc. Process for synthesizing carbapenem antibiotics

Also Published As

Publication number Publication date
CA2427762C (en) 2009-10-20
US20040054167A1 (en) 2004-03-18
ATE322495T1 (de) 2006-04-15
US7078534B2 (en) 2006-07-18
EA200300520A1 (ru) 2003-10-30
BG107852A (bg) 2004-01-30
AU2002212591A1 (en) 2002-05-15
PT1334105E (pt) 2006-08-31
EP1334105A1 (en) 2003-08-13
CN1481384A (zh) 2004-03-10
JP2004525084A (ja) 2004-08-19
EE200300206A (et) 2003-10-15
CA2427762A1 (en) 2002-05-10
KR20030059812A (ko) 2003-07-10
EP1334105B1 (en) 2006-04-05
WO2002036594A1 (en) 2002-05-10
IN191798B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2004-01-03
ZA200303338B (en) 2004-03-09
ES2261494T3 (es) 2006-11-16
CN100445284C (zh) 2008-12-24
DK1334105T3 (da) 2006-08-14
EA006442B1 (ru) 2005-12-29
MXPA03003916A (es) 2004-01-29

Similar Documents

Publication Publication Date Title
DE60141706D1 (de) Verbindungen mit fungizider wirkung und verfahren zur ihrer herstellung und verwendung
DE60118593D1 (de) Verfahren zur herstellung von kristallinem n-formimidoylthienamycin-monohydrat (imipenem-monohydrat)
ATE318139T1 (de) Dipeptidylpeptidase-hemmer zur behandlung von diabetes
WO2004013120A8 (en) Novel benzodioxoles
ATE306252T1 (de) Verfahren zur herstellung kristalliner partikel zur inhalation
EA200200510A1 (ru) 4-карбоксиамино-2-этил-1,2,3,4-тетрагидрохинолин в кристаллической форме как ингибитор сетр
MXPA05010433A (es) Derivados de pirrolidina y procedimiento para prepararlos.
MXPA04004604A (es) Proceso para la preparacion de imipenem cristalino.
DE60236207D1 (de) Verfahren zur herstellung von phenserin und dessen analogon
DE60125378D1 (de) Verfahren zur herstellung von 2-aminomethyl-halogen-pyridinen
ATE373666T1 (de) Verfahren zur reinigung eines cephalosporin- derivats
DE60015563D1 (de) Verfahren zur herstellung von benzoperhydroisoindolen
ATE266618T1 (de) Verfahren zur herstellung von zwischenprodukten für pestizide
ATE292135T1 (de) Neues verfahren zur herstellung von vinyl- pyrrolidinon cephalosporin derivate
DE60233130D1 (de) Verfahren zur herstellung von imipenem
ATE549315T1 (de) Verfahren zur herstellung von kristallinem perindopril
DE602004008486D1 (de) Verfahren zur herstellung von (1s,4r)-cis-4-ä2-amino-6-chlor-9h-purin-9-ylü-2-cyclopenten-1-methanol
MXPA03010548A (es) Proceso para el aislamiento de imipenem cristalino.
ATE299851T1 (de) Verfahren zur herstellung von zwischenprodukten
DE60107292D1 (de) Verfahren zur herstellung von (+)-trans-4-p-fluorophenyl-3-hydroxymethyl-1-methylpiperidin
GB9920959D0 (en) Novel process
DE60325390D1 (de) Verfahren zur herstellung von zwischenprodukten
MY134151A (en) Process for the preparation of crystalline n-formimindoyl thienamycin monohydrate (imipenem monohydrate)
MXPA06001115A (es) Un proceso nuevo para la preparacion de imipenem.
DE69514512D1 (de) Verfahren zur herstellung von benzopyranderivaten

Legal Events

Date Code Title Description
8332 No legal effect for de